Cart
sales@molnova.com
ICA-105574
CAS No. 316146-57-3
ICA-105574 ( ICA; 3-nitro-N-[4-phenoxyphenyl]-benzamide )
Catalog No. M24250 CAS No. 316146-57-3
ICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 76 | In Stock |
|
| 10MG | 132 | In Stock |
|
| 25MG | 282 | In Stock |
|
| 50MG | 444 | In Stock |
|
| 100MG | 651 | In Stock |
|
| 500MG | 1368 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameICA-105574
-
NoteResearch use only, not for human use.
-
Brief DescriptionICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
-
DescriptionICA-105574 is an activator of hERG that binds to the channel to remove inactivation, thus increasing peak current amplitude and shortening the action potential. It also modulates activation kinetics of the channel.
-
SynonymsICA; 3-nitro-N-[4-phenoxyphenyl]-benzamide
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorhERG
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number316146-57-3
-
Formula Weight334.3
-
Molecular FormulaC19H14N2O4
-
Purity>98% (HPLC)
-
SolubilityDMSO:10 mM
-
SMILESC1=CC=C(C=C1)OC2=CC=C(C=C2)NC(=O)C3=CC(=CC=C3)[N+](=O)[O-]
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Meng J , Shi C , Li L , et al. Compound ICA-105574 prevents arrhythmias induced by cardiac delayed repolarization[J]. European Journal of Pharmacology, 2013, 718(1-3):87-97.
molnova catalog
related products
-
JCN037
JCN037 is potent, non-covalent and brain-penetrant inhibitor of EGFR(EGFR, p-wtEGFR and pEGFRvⅢ with IC50 of 2.49 nM, 3.95 nM, 4.48 nM , respectively).
-
JBJ-04-125-02
JBJ-04-125-02 is a potent, mutant-selective, allosteric and orally active EGFR inhibitor with an IC50 of 0.26 nM for EGFRL858R/T790M. JBJ-04-125-02 can inhibit cancer cell proliferation and EGFRL858R/T790M/C797S signaling. JBJ-04-125-02 has anti-tumor activities.
-
BPR1J-097
BPR1J-097 is a novel FLT-3 inhibitor(IC50: 11±7 nM) with promising in vivo anti-tumor activities. It also inhibits FLT-3 D835Y (IC50: 3 nM).
